Gastric Ulcers Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Gastric Ulcers Drugs in Development Report Overview

A gastric ulcer is a painful sore or ulcer in the lining of the stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting, and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids.

The Gastric Ulcers pipeline drugs market research report provides comprehensive information on the therapeutics under development for Gastric Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects.

Key Targets in the Gastric Ulcers Pipeline Products Market

The key targets in the Gastric Ulcers pipeline products market are Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K, Prostaglandin G/H Synthase 2, Epidermal Growth Factor Receptor, and Prostaglandin G/H Synthase 1.

Gastric Ulcers Pipeline Products Market Analysis by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Gastric Ulcers Pipeline Products Market

The key mechanisms of action in the Gastric Ulcers pipeline products market are Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Epidermal Growth Factor Receptor Agonist, and Prostaglandin G/H Synthase 1 Inhibitor.

Gastric Ulcers Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the Gastric Ulcers Pipeline Products Market

The key routes of administration in the Gastric Ulcers pipeline products market are oral, intravenous, and parenteral.

Gastric Ulcers Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Gastric Ulcers Pipeline Products Market

The key molecule types in the Gastric Ulcers pipeline products market are small molecule and fusion protein.

Gastric Ulcers Pipeline Products Market Analysis by Molecule Types

For more molecule type insights, download a free report sample

Major Companies in the Gastric Ulcers Pipeline Products Market

Some of the major companies in the Gastric Ulcers pipeline products market are Jiangsu Carephar Pharmaceutical Co Ltd, XuanZhu Biological Technology Co Ltd, Axsome Therapeutics Inc, Daewoong Co Ltd, FortuneRock (China) Ltd, Hunan Sailong Pharmaceutical Co Ltd, Jiangsu Aosaikang Pharmaceutical Co Ltd, Korea Pharma Co Ltd, Kukje Pharmaceutical Industry Co Ltd, and PharmaKing Co Ltd.

Axsome Therapeutics Inc: Axsome Therapeutics Inc (Axsome) is a biopharmaceutical company that develops and commercializes therapies for the treatment of central nervous system (CNS) disorders. The company’s pipeline product portfolio comprises AXS-05, for the treatment of resistant depression, smoking cessation, and agitation in Alzheimer’s disease, AXS-07, for the treatment of migraine, AXS-12, for symptoms of narcolepsy, and AXS-14, for the treatment of fibromyalgia. The company supplies its products through internal sales, distributors, and an internal marketing group in the US and outside the US. Axsome is headquartered in New York, the US.

Gastric Ulcers Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Ulcers (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Gastric Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Gastric Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Gastric Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Gastric Ulcers (Gastrointestinal)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Gastric Ulcers (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Gastric Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.